Palisade Bio
PALI1.8953.32% ( -0.065 )
Palisade Bio (PALI)
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery...
- Open
- 1.940
- High
- 1.950
- Low
- 1.855
- Prev. Close
- 1.960
- Volume
- 1.85M
- Turnover
- 3.50M
- Avg Price
- 1.888
- Bid/Ask Ratio
- --
- Amplitude
- 4.85%
- 52wk High
- 2.855
- Volume Ratio
- 0.61
- Turnover Ratio
- 1.39%
Palisade Bio Analyst Rating
View MoreForecast & Rating
Jul 23, 2026Price forecast
$10.22439.43%
Forecast & RatingStrong buy
9analysts
- Strong buy77.78%
- Buy22.22%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · Jul 23 at 01:06 PM
Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2
- benzinga_article · Jul 23 at 06:29 AM
This Signet Jewelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- Market Beat · Jul 20 at 03:14 AM
Palisade Bio, Inc. (NASDAQ:PALI) Given Average Recommendation of "Buy" by Analysts
- PUBT · Jul 10 at 05:15 PM
Palisade Bio director Robert Baltera Jr acquires USD 88,687.50 in common shares
- PUBT · Jul 10 at 08:00 AM
Palisade Bio to meet investors at Leerink Partners Therapeutics Forum July 14-15
- Tip Ranks · Jul 8 at 09:02 PM
Insider Move: Palisade Bio Director Makes Bold New Stock Bet
